Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.

The EMBO journal - 11 Jul 2007

Tanaka Tomoyuki, Williams Roger L, Rabbitts Terence H

Abstract excerpt

Many disease-related processes occur via protein complexes that are considered undruggable with small molecules. An example is RAS, which is frequently mutated in cancer and contributes to initiation and maintenance of the disease by constitutive signal transduction through protein interaction with effector proteins, like PI3K, RAF and RALGDS. Such protein interactions are therefore significant targets for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neoplasm
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chlorocebus aethiops

Share to Crystallography, X-Ray

Share to Protein Structure, Quaternary

Share to ras Proteins

Share to Surface Plasmon Resonance

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 17568777
DOI: 10.1038/sj.emboj.7601744
PMCID: PMC1914092

Genes

RALGDS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.PMID 17568777Read ↗

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.Semantic proximity Read ↗

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.Semantic proximity Read ↗

Targeting Ras with protein engineering.Semantic proximity Read ↗

Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.Semantic proximity Read ↗

Small molecule inhibitors of RAS proteins with oncogenic mutations.Semantic proximity Read ↗

An engineered protein antagonist of K-Ras/B-Raf interaction.Semantic proximity Read ↗

An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth.Semantic proximity Read ↗

Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth.Semantic proximity Read ↗

Inhibition of tumor growth by a novel engineered chimeric toxin that cleaves activated mutant and wild-type RASSemantic proximity Read ↗

Small-molecule modulation of Ras signaling.Semantic proximity Read ↗

A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers.Semantic proximity Read ↗

Intracellular antibodies and cancer: New technologies offer therapeutic opportunitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.